Literature DB >> 2825716

Differential induction of human liver UDP-glucuronosyltransferase activities by phenobarbital-type inducers.

K W Bock1, B S Bock-Hennig.   

Abstract

(1) UDP-glucuronosyltransferase (UDP-GT) activities and their inducibility were investigated in human liver microsomes from a "liver bank". (2) UDP-GT activities were differentially induced in liver microsomes from patients treated with the phenobarbital-type inducers phenytoin or pentobarbital. UDP-GT activity towards bilirubin was induced 3-fold. Enzyme activities towards paracetamol, benzo(a)pyrene-3,6-quinol, 4-methylumbelliferone and 1-naphthol were moderately induced and to similar extents (2-fold). In contrast, morphine and 4-hydroxybiphenyl glucuronidation were not significantly affected. Cytochrome P-450 dependent 7-ethoxycoumarin O-deethylase was increased 5-fold. (3) A human hepatoma cell line (Hep G2) was studied to obtain information on the inducibility of human UDP-GT activities by 3-methylcholanthrene-type inducers. UDP-GT activities towards benzo(a)pyrene-3,6-quinol and 1-naphthol were moderately but significantly induced by 3-methylcholanthrene-treatment of the cells (2-fold), whereas 7-ethoxyresorufin O-deethylase and 7-ethoxycoumarin O-deethylase were increased over 100- and 10-fold, respectively. (4) The results suggest the existence of differentially inducible UDP-GT isoenzymes in human liver. The findings may be useful as a guide to characterize human liver UDP-GT isoenzymes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2825716     DOI: 10.1016/0006-2952(87)90572-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  12 in total

Review 1.  Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction.

Authors:  M Strolin Benedetti; R Whomsley; E Baltes; F Tonner
Journal:  Eur J Clin Pharmacol       Date:  2005-11-24       Impact factor: 2.953

2.  Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells.

Authors:  D Harding; S Fournel-Gigleux; M R Jackson; B Burchell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

Review 3.  Human hepatocytes as a key in vitro model to improve preclinical drug development.

Authors:  G Fabre; J Combalbert; Y Berger; J P Cano
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

4.  Glucuronidation of 7-hydroxy-4-methylcoumarin by human liver microsomes. Inhibition by certain drugs.

Authors:  Y M Irshaid; K I Gharaybeh; F F Ammari; N M Rawashdeh
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

5.  Expression of a high-affinity form of UDP-glucuronosyltransferase in human foetal liver cells in culture on exposure to mercuric chloride.

Authors:  T M Tan; K P Wong; K H Sit
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

6.  Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver.

Authors:  S L Nyberg; R P Remmel; H J Mann; M V Peshwa; W S Hu; F B Cerra
Journal:  Ann Surg       Date:  1994-07       Impact factor: 12.969

Review 7.  Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.

Authors:  H K Kroemer; U Klotz
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

Review 8.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

9.  A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.

Authors:  P J McKee; J Blacklaw; G Forrest; R A Gillham; S M Walker; D Connelly; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

10.  Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase.

Authors:  J Seppen; P J Bosma; B G Goldhoorn; C T Bakker; J R Chowdhury; N R Chowdhury; P L Jansen; R P Oude Elferink
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.